P-238 A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/ refractory multiple myeloma (RRMM)

Michèle Cavo; Michel Delforge; Meletios A Dimopoulos; Fernando Escalante; Malin Hultcrantz; David Kleinman; Hans C. Lee; Ravi Vij; Nirali Kotowsky; Leena Camadoo-O'Byrne; Jacopo Bitetti; Tim D'Estrube; Mark Fry; Carla Y. Vossen

doi:10.1016/s2152-2650(23)01856-6

Related publications

Article2025

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

María-Victoria Mateos, Vânia Hungria, Meral Beksaç, Paweł Robak, Kihyun Kım, Sergey Voloshin, Hanlon Sia, Esther González García, Gracia Martínez, Chang‐Ki Min, Marcelo Pitombeira de Lacerda, Anna Sureda Balarí, Ivan Špıčka, Sosana Delimpasi, Marek Hus, Vera Zherebtsova, Christopher Wård, Phoebe Joy Ho, Roman Hájek, Sebastian Grosicki, S. Yousuf Zafar, Al-Ola Abdallah, Jorge Mouro, Zeyad Khalaf, Hena Baig, Ainslee Moore, Chee Paul Lin, Maureen Nichols, Ianire Garrobo-Calleja, Sybil Varghese, Nick Pirooz, Shing Yip Lee, Lydia Eccersley, Elisabet E. Manasanch, Luděk Pour, Meletios A Dimopoulos

Article2024

P-395 Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

Vânia Hungria, Katja Weisel, Atanas Radinoff, Sosana Delimpasi, Gábor Mikala, Tamás Masszi, Jian Li, Marcelo Capra, Ângelo Maiolino, Vasiliki Pappa, Dominik Chraniuk, Iurii Osipov, Xavier Leleu, Michael Löw, Fotini M. Kouri, John Liboon, Chris Brawley, Eric Lewis, Gabriela Tubel, Mary Li, Astrid McKeown, Sumita Roy–Ghanta,

Article2023

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Sireesha Asoori, Rakesh Popat, Joaquín Martínez‐López, Efstathios Kastritis, Larissa Brunaldi, Radhika Bansal, Andre De Menezes Silva Corraes, Kwee Yong, Catriona Mactier, Magdalena Corona, Adolfo Jesús Sáez Marín, Despina Fotiou, Meletios A Dimopoulos, Saurabh Chhabra, Sikander Ailawadhi, Ricardo Parrondo, Thomas G. Martin, Brian G.M. Durie, Yi Lin

Article2023

P-301 Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma

Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Μαρία Ρούσσου, Evangelos Eleutherakis‐Papaiakovou, Foteini Theodorakakou, Vassiliki Spiliopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos, Maria Gavriatopoulou

Article2020

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Ajay K. Nooka, Keith Stockerl‐Goldstein, Rafat Abonour, Ryan Ramaekers, Amit Khot, Adam Forbes, Cindy Lee, Bradley Augustson, Andrew Spencer, María‐Victoria Mateos, Bikramjit Chopra, Rachel Rogers, Deborah A. Smith, Jacqueline Davidge, Rocío Montes de, Geraldine Ferron‐Brady, Anne Yeakey, Mala K. Talekar, Brandon E. Kremer, Ira Gupta,